Form 4 for VTGN Vistagen Therapeutics, Inc.
Accepted 2022-05-16 00:00:00 ET · period of report 2022-05-12 · accession 0001415889-22-004988 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-16 | 2022-05-12 | VTGN | Singh Shawn | CEO, Dir | M - OptEx | $1.00 | +100.0K | 149.0K | +204% | +$100.0K |
| D | 2022-05-16 | 2022-05-12 | VTGN | Singh Shawn | CEO, Dir | M - OptEx | $0.00 | -100.0K | 70.0K | -59% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-12 | M | A | 100,000 | $1.00 | 148,998 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-05-12 | M | D | 100,000 | $0.00 | 70,000 | D | $1.00 · — to 2029-09-05 | 100,000 Common Stock | (F1) Stock option vested 25% on the grant date of September 5, 2019, with the remainder vesting monthly over the 36 months thereafter. |